News

Novo Nordisk bags drug delivery platform
Enlarge image

BusinessDenmark

Novo Nordisk bags drug delivery platform

03.05.2012 - Denmark’s Novo Nordisk has exclusively licensed Caisson's heparosan-based drug delivery to develop compounds of its drug pipeline.

Oklahoma City/Austin/Baegsvard – With the exclusive license deal, Novo Nordisk has secured a key platform to extend the life cycle of its existing drugs by simply attaching them to bio-inert sugar polymers, which cannot be degraded extra-cellularly. Under the terms of the agreement, Caisson Biotech LLC, a wholly owned subsidiary of Heparinex, L.L.C, will receive an undisclosed upfront payment from the Danish drugmaker plus fees for contract research and manufacturing. In addition, Caisson will be eligible to receive milestone payments upon achievement of certain predefined clinical, regulatory and commercial targets, plus royalties on the global sales of the therapeutic products developed under the agreement, representing a total deal value of more than $100m. 

Caisson’s drug delivery technology, who was invented by the firm’s CSO Dr. Paul DeAngelis at the University of Oklahoma, utilises heparosan, a naturally occurring sugar polymer that is stable and inert in the bloodstream, but is biodegradable inside cells for the purpose of cloaking, enlarging and/or protecting drug cargo. Heparosan can be customised with respect to polymer size and conjugation chemistry, thus increasing product half-life, reducing immunogenicity, and increasing stability. 

In contrast to PEGylation, heparosanylation shows no toxicity. Additionally, Caisson Biotech claims higher and faster water solubility, longer excretion half life and its larger flexibility concerning usage to different drug types and delivery systems.

http://www.european-biotechnology-news.com/news/news/2012-02/novo-nordisk-bags-drug-delivery-platform-for-100m.html

FinancingUK

23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.

R&DDenmark

19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.

ResearchUKEU

17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).

Stock marketsGermany

15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).

LicensingDenmark

11.08.2016 Danish Genmab AS has granted Gilead Sciences license to use its DuoBody technology platform to develop bispecific antibodies for the treatment of HIV. The deal is worth up to €252m.

Clinical developmentHungaryIreland

09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.

ImmunotherapySpain

08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.

ApprovalEU

04.08.2016 After a two-year pilot period, the EMA has published its report on its adaptive pathways approach. The agency plans to “explore the concept further” and will continue to accept proposals.

BusinessPolandUK

01.08.2016 Life science venture capital group Epidarex has launched Nodthera Ltd, a biotech based on research by Poland-based drug discovery company Selvita. The start-up aims to develop novel inhibitors of the NLRP3 inflammasome.

R&DUKIreland

29.07.2016 GlaxoSmithKline has in-licensed Janssen’s anti-IL-33R monoclonal antibody for severe asthma. The British drugmaker is paying €208m up front for the mAb.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLMED (I)0.39 EUR11.43%
  • CERENIS THERAPEUTICS HOLDING SA (F)7.51 EUR10.77%
  • SYNGENTA (CH)421.20 CHF10.61%

FLOP

  • RENEURON (UK)2.62 GBP-9.03%
  • BIONOR PHARMA (N)0.48 NOK-7.69%
  • ZEALAND PHARMA (DK)113.50 DKK-6.58%

TOP

  • DIAMYD MEDICAL -B- (S)7.15 SEK70.2%
  • KARO BIO (S)37.80 SEK31.7%
  • NEUROVIVE PHARMACEUTICAL AB (S)5.80 SEK25.0%

FLOP

  • BIONOR PHARMA (N)0.48 NOK-21.3%
  • NOVOZYMES (DK)286.90 DKK-13.5%
  • RENEURON (UK)2.62 GBP-12.7%

TOP

  • KARO BIO (S)37.80 SEK2420.0%
  • NICOX (F)10.12 EUR459.1%
  • SAREUM HOLDINGS (UK)0.76 GBP261.9%

FLOP

  • BB BIOTECH (D)45.12 EUR-81.0%
  • EVOCUTIS (UK)0.04 GBP-78.9%
  • NOVACYT (F)1.29 EUR-70.6%

No liability assumed, Date: 23.08.2016